$2.50
1.66% today
Nasdaq, Aug 12, 04:43 pm CET
ISIN
US98973P1012
Symbol
TCRT

ZIOPHARM Oncology, Inc. Stock price

$2.54
-2.45 49.10% 1M
+0.88 52.84% 6M
+0.64 33.33% YTD
+0.06 2.42% 1Y
-264.46 99.05% 3Y
-505.96 99.50% 5Y
-1,575.46 99.84% 10Y
-13.46 84.13% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.07 2.83%
ISIN
US98973P1012
Symbol
TCRT
Industry

Key metrics

Basic
Market capitalization
$5.0m
Enterprise Value
$4.7m
Net debt
positive
Cash
$320.0k
Shares outstanding
1.6m
Valuation (TTM | estimate)
P/E
negative | 2.9
P/S
502.5 | 0.0
EV/Sales
470.5 | 0.0
EV/FCF
negative
P/B
4.7
Financial Health
Equity Ratio
74.9%
Return on Equity
-226.8%
ROCE
-392.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$10.0k | $568.1m
EBITDA
$-4.2m | -
EBIT
$-4.2m | $138.8m
Net Income
$-4.1m | $1.4m
Free Cash Flow
$-3.8m
Growth (TTM | estimate)
Revenue
0.0% | 5,680,500.0%
EBITDA
83.2% | -
EBIT
84.2% | 2,985.0%
Net Income
84.8% | 129.9%
Free Cash Flow
83.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-41,630.0% | -
EBIT
-41,630.0%
Net
-40,710.0% | 0.3%
Free Cash Flow
-38,260.0%
More
EPS
$-2.5
FCF per Share
$-2.4
Short interest
3.7%
Employees
1
Rev per Employee
$10.0k
Show more

Is ZIOPHARM Oncology, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

ZIOPHARM Oncology, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:

Hold
50%
Sell
50%

Financial data from ZIOPHARM Oncology, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.01 0.01
0% 0%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.59 3.59
66% 66%
35,900%
- Research and Development Expense 0.67 0.67
93% 93%
6,700%
-4.16 -4.16
83% 83%
-41,600%
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -4.16 -4.16
84% 84%
-41,630%
Net Profit -4.07 -4.07
85% 85%
-40,700%

In millions USD.

Don't miss a Thing! We will send you all news about ZIOPHARM Oncology, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ZIOPHARM Oncology, Inc. Stock News

Neutral
GlobeNewsWire
about 2 months ago
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) i...
Neutral
GlobeNewsWire
3 months ago
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced its planned filing of a Schedule 13D with the U.S. Securities and Exchange Commission disclosing beneficial ownership of common stock in Alaunos Therapeutics, Inc. (Nasdaq: TCRT).

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Head office United States
CEO Dale Hogue
Employees 1
Founded 2003
Website alaunos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today